ReP USP - Resultado da busca

Artigo de periodico
Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats (2023)
Cavichioli, Andreza M.; Silva, Thamyris Santos; Grace, Anthony A.; Guimarães, Francisco Silveira ; Gomes, Felipe Villela
Source: Schizophrenia Bulletin. Unidade: FMRP
Subjects: POTENCIAIS DE AÇÃO, NEUROTRANSMISSORES, ESQUIZOFRENIA, HIPOCAMPO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CAVICHIOLI, Andreza M. et al. Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats. Schizophrenia Bulletin, v. 49, n. 1, p. 68-77, 2023Tradução . . Disponível em: https://doi.org/10.1093/schbul/sbac106. Acesso em: 09 jun. 2024.
APA
Cavichioli, A. M., Silva, T. S., Grace, A. A., Guimarães, F. S., & Gomes, F. V. (2023). Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats. Schizophrenia Bulletin, 49( 1), 68-77. doi:10.1093/schbul/sbac106
NLM
Cavichioli AM, Silva TS, Grace AA, Guimarães FS, Gomes FV. Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats [Internet]. Schizophrenia Bulletin. 2023 ; 49( 1): 68-77.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1093/schbul/sbac106
Vancouver
Cavichioli AM, Silva TS, Grace AA, Guimarães FS, Gomes FV. Levetiracetam attenuates adolescent stress-induced behavioral and electrophysiological changes associated with schizophrenia in adult rats [Internet]. Schizophrenia Bulletin. 2023 ; 49( 1): 68-77.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1093/schbul/sbac106
Artigo de periodico
The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol (2023)
Hartmann, Alice; Vila-Verde, Carla ; Guimarães, Francisco Silveira ; Wegener, Sâmia Regiane Lourenço Joca ; Lisboa, Sabrina Francesca de Souza
Source: Current Neuropharmacology. Unidades: FMRP, FCFRP, IRI
Subjects: CANABINOIDES, INFLAMAÇÃO, TECIDO NERVOSO, DEGENERAÇÃO NEURAL, DOENÇAS DO SISTEMA NERVOSO, TRANSTORNOS PSICÓTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HARTMANN, Alice et al. The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol. Current Neuropharmacology, v. 21, n. 2, p. 284-308, 2023Tradução . . Disponível em: https://doi.org/10.2174/1570159X20666220411101217. Acesso em: 09 jun. 2024.
APA
Hartmann, A., Vila-Verde, C., Guimarães, F. S., Wegener, S. R. L. J., & Lisboa, S. F. de S. (2023). The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol. Current Neuropharmacology, 21( 2), 284-308. doi:10.2174/1570159X20666220411101217
NLM
Hartmann A, Vila-Verde C, Guimarães FS, Wegener SRLJ, Lisboa SF de S. The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol [Internet]. Current Neuropharmacology. 2023 ; 21( 2): 284-308.[citado 2024 jun. 09 ] Available from: https://doi.org/10.2174/1570159X20666220411101217
Vancouver
Hartmann A, Vila-Verde C, Guimarães FS, Wegener SRLJ, Lisboa SF de S. The NLRP3 inflammasome in stress response: another target for the promiscuous cannabidiol [Internet]. Current Neuropharmacology. 2023 ; 21( 2): 284-308.[citado 2024 jun. 09 ] Available from: https://doi.org/10.2174/1570159X20666220411101217
Artigo de periodico
Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) (2022)
Souza, José Diogo Ribeiro de; Pacheco, Júlia Cozar; Rossi, Giordano Novak ; Paulo, Bruno O. de; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza ; Santos, Rafael Guimarães dos
Source: Pharmaceutics. Unidade: FMRP
Subjects: CANABINOIDES, INTERAÇÃO DE MEDICAMENTOS, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, José Diogo Ribeiro de et al. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, v. 14, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.3390/pharmaceutics14122598. Acesso em: 09 jun. 2024.
APA
Souza, J. D. R. de, Pacheco, J. C., Rossi, G. N., Paulo, B. O. de, Zuardi, A. W., Guimarães, F. S., et al. (2022). Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022). Pharmaceutics, 14, 1-14. doi:10.3390/pharmaceutics14122598
NLM
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3390/pharmaceutics14122598
Vancouver
Souza JDR de, Pacheco JC, Rossi GN, Paulo BO de, Zuardi AW, Guimarães FS, Hallak JEC, Crippa JA de S, Santos RG dos. Adverse effects of oral cannabidiol: an updated systematic review of randomized controlled trials (2020–2022) [Internet]. Pharmaceutics. 2022 ; 14 1-14.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3390/pharmaceutics14122598
Artigo de periodico
Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors (2022)
Souza, Adriana de Jesus; Cortez, Isadora L.; Silva, Nicole R.; Pedrazzi, João Francisco Cordeiro; Domingos, Luana B.; Braga, Matheus Silva; Silva, Thamyris Santos; Del Bel, Elaine Aparecida ; Resstel, Leonardo Barbosa Moraes ; Li, Guanguan; Mian, Md Yeunus; Sharmin, Dishary; Guimarães, Francisco Silveira ; Cook, James M.; Gomes, Felipe Villela
Source: Behavioural Brain Research. Unidades: FORP, FMRP
Subjects: ANSIEDADE, DEPRESSÃO, ANTIPSICÓTICOS, ESQUIZOFRENIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Adriana de Jesus et al. Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors. Behavioural Brain Research, v. 428, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.bbr.2022.113832. Acesso em: 09 jun. 2024.
APA
Souza, A. de J., Cortez, I. L., Silva, N. R., Pedrazzi, J. F. C., Domingos, L. B., Braga, M. S., et al. (2022). Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors. Behavioural Brain Research, 428, 1-11. doi:10.1016/j.bbr.2022.113832
NLM
Souza A de J, Cortez IL, Silva NR, Pedrazzi JFC, Domingos LB, Braga MS, Silva TS, Del Bel EA, Resstel LBM, Li G, Mian MY, Sharmin D, Guimarães FS, Cook JM, Gomes FV. Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors [Internet]. Behavioural Brain Research. 2022 ; 428 1-11.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.bbr.2022.113832
Vancouver
Souza A de J, Cortez IL, Silva NR, Pedrazzi JFC, Domingos LB, Braga MS, Silva TS, Del Bel EA, Resstel LBM, Li G, Mian MY, Sharmin D, Guimarães FS, Cook JM, Gomes FV. Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABAA receptors [Internet]. Behavioural Brain Research. 2022 ; 428 1-11.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.bbr.2022.113832
Artigo de periodico
Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters (2022)
Crippa, José Alexandre de Souza ; Pereira Junior, Luiz C.; Pereira, Lívia C.; Zimmermann, Patrícia M.; Brum Júnior, Liberato; Rechia, Letícia Mello; Dias, Isabella Caroline da Silva; Hallak, Jaime Eduardo Cecilio ; Campos, Alline Cristina de; Guimarães, Francisco Silveira ; Queiroz, Regina Helena Costa; Zuardi, Antonio Waldo
Source: Brazilian Journal of Psychiatry. Unidades: FMRP, FCFRP
Subjects: CANABINOIDES, FARMACOTERAPIA, FARMACODINÂMICA, MÉTODO DUPLO-CEGO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. Brazilian Journal of Psychiatry, v. 44, n. 1, p. 15-20, 2022Tradução . . Disponível em: https://doi.org/10.1590/1516-4446-2020-1684. Acesso em: 09 jun. 2024.
APA
Crippa, J. A. de S., Pereira Junior, L. C., Pereira, L. C., Zimmermann, P. M., Brum Júnior, L., Rechia, L. M., et al. (2022). Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. Brazilian Journal of Psychiatry, 44( 1), 15-20. doi:10.1590/1516-4446-2020-1684
NLM
Crippa JA de S, Pereira Junior LC, Pereira LC, Zimmermann PM, Brum Júnior L, Rechia LM, Dias IC da S, Hallak JEC, Campos AC de, Guimarães FS, Queiroz RHC, Zuardi AW. Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters [Internet]. Brazilian Journal of Psychiatry. 2022 ; 44( 1): 15-20.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1590/1516-4446-2020-1684
Vancouver
Crippa JA de S, Pereira Junior LC, Pereira LC, Zimmermann PM, Brum Júnior L, Rechia LM, Dias IC da S, Hallak JEC, Campos AC de, Guimarães FS, Queiroz RHC, Zuardi AW. Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters [Internet]. Brazilian Journal of Psychiatry. 2022 ; 44( 1): 15-20.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1590/1516-4446-2020-1684
Artigo de periodico
Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity (2022)
Carvalho, Renata K.; Rocha, Thiago L.; Fernandes, Fábio H.; Gonçalves, Bruno B.; Souza, Maingredy R.; Araújo, Amanda A.; Barbosa, Caio C.; Silva, Daniela M.; Campos, Hericles M.; Tomazett, Mariana V.; Ghedini, Paulo C.; Guimarães, Francisco Silveira ; Andersen, Monica L.; Santos, Fernanda C. A.; Costa, Renata Mazaro
Source: Chemico-Biological Interactions. Unidades: FMRP, FCF
Subjects: CANABINOIDES, DANO AO DNA, ESPERMATOGÊNESE, ESPERMATOZOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARVALHO, Renata K. et al. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity. Chemico-Biological Interactions, v. 351, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.cbi.2021.109743. Acesso em: 09 jun. 2024.
APA
Carvalho, R. K., Rocha, T. L., Fernandes, F. H., Gonçalves, B. B., Souza, M. R., Araújo, A. A., et al. (2022). Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity. Chemico-Biological Interactions, 351. doi:10.1016/j.cbi.2021.109743
NLM
Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, Barbosa CC, Silva DM, Campos HM, Tomazett MV, Ghedini PC, Guimarães FS, Andersen ML, Santos FCA, Costa RM. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity [Internet]. Chemico-Biological Interactions. 2022 ; 351[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.cbi.2021.109743
Vancouver
Carvalho RK, Rocha TL, Fernandes FH, Gonçalves BB, Souza MR, Araújo AA, Barbosa CC, Silva DM, Campos HM, Tomazett MV, Ghedini PC, Guimarães FS, Andersen ML, Santos FCA, Costa RM. Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: new insights of cannabidiol-mediated male reproductive toxicity [Internet]. Chemico-Biological Interactions. 2022 ; 351[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.cbi.2021.109743
Artigo de periodico
Case report: cannabidiol-induced skin rash: a case series and key recommendations (2022)
Souza, José Diogo dos Santos; Fassoni-Ribeiro, Maíra; Batista, Rayssa Miranda; Ushirohira, Juliana Mayumi; Zuardi, Antonio Waldo; Guimarães, Francisco Silveira ; Campos, Alline Cristina de; Osório, Flávia de Lima ; Elias, Daniel; Souza, Cacilda da Silva; Fassoni, Andréa Aparecida; Hallak, Jaime Eduardo Cecilio ; Crippa, José Alexandre de Souza
Source: Frontiers in Pharmacology. Unidade: FMRP
Subjects: CANABINOIDES, INTERAÇÃO DE MEDICAMENTOS, FERIMENTOS E LESÕES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, José Diogo dos Santos et al. Case report: cannabidiol-induced skin rash: a case series and key recommendations. Frontiers in Pharmacology, v. 13, p. 1-6, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.881617. Acesso em: 09 jun. 2024.
APA
Souza, J. D. dos S., Fassoni-Ribeiro, M., Batista, R. M., Ushirohira, J. M., Zuardi, A. W., Guimarães, F. S., et al. (2022). Case report: cannabidiol-induced skin rash: a case series and key recommendations. Frontiers in Pharmacology, 13, 1-6. doi:10.3389/fphar.2022.881617
NLM
Souza JD dos S, Fassoni-Ribeiro M, Batista RM, Ushirohira JM, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Elias D, Souza C da S, Fassoni AA, Hallak JEC, Crippa JA de S. Case report: cannabidiol-induced skin rash: a case series and key recommendations [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-6.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3389/fphar.2022.881617
Vancouver
Souza JD dos S, Fassoni-Ribeiro M, Batista RM, Ushirohira JM, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Elias D, Souza C da S, Fassoni AA, Hallak JEC, Crippa JA de S. Case report: cannabidiol-induced skin rash: a case series and key recommendations [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-6.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3389/fphar.2022.881617
Artigo de periodico
Spontaneous activity of CB2 receptors attenuates stress-induced behavioral and neuroplastic deficits in male mice (2022)
Ribeiro, Melissa A.; Aguiar, Rafael P.; Scarante, Franciele Franco ; Fusse, Eduardo J.; Oliveira, Rubia M. W. de; Guimarães, Francisco Silveira ; Campos, Alline Cristina de
Source: Frontiers in Pharmacology. Unidade: FMRP
Subjects: ESTRESSE, ANTIDEPRESSIVOS, HIPOCAMPO, COMPORTAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Melissa A. et al. Spontaneous activity of CB2 receptors attenuates stress-induced behavioral and neuroplastic deficits in male mice. Frontiers in Pharmacology, v. 12, p. 1-14, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2021.805758. Acesso em: 09 jun. 2024.
APA
Ribeiro, M. A., Aguiar, R. P., Scarante, F. F., Fusse, E. J., Oliveira, R. M. W. de, Guimarães, F. S., & Campos, A. C. de. (2022). Spontaneous activity of CB2 receptors attenuates stress-induced behavioral and neuroplastic deficits in male mice. Frontiers in Pharmacology, 12, 1-14. doi:10.3389/fphar.2021.805758
NLM
Ribeiro MA, Aguiar RP, Scarante FF, Fusse EJ, Oliveira RMW de, Guimarães FS, Campos AC de. Spontaneous activity of CB2 receptors attenuates stress-induced behavioral and neuroplastic deficits in male mice [Internet]. Frontiers in Pharmacology. 2022 ; 12 1-14.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3389/fphar.2021.805758
Vancouver
Ribeiro MA, Aguiar RP, Scarante FF, Fusse EJ, Oliveira RMW de, Guimarães FS, Campos AC de. Spontaneous activity of CB2 receptors attenuates stress-induced behavioral and neuroplastic deficits in male mice [Internet]. Frontiers in Pharmacology. 2022 ; 12 1-14.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3389/fphar.2021.805758
Artigo de periodico
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic (2022)
Souza, José Diogo dos Santos; Zuardi, Antonio Waldo; Guimarães, Francisco Silveira ; Osório, Flávia de Lima ; Loureiro, Sonia Regina ; Campos, Alline Cristina de; Hallak, Jaime Eduardo Cecilio ; Santos, Rafael Guimarães dos ; Silveira, Isabella Lara Machado ; Lima, Karina Pereira; Pacheco, Júlia Cozar; Ushirohira, Juliana Mayumi; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira; Scarante, Franciele Franco ; Santos, Isabela Pires dos; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antonio Lopes da; Esposito, Danillo Lucas Alves ; Andraus, Maristela Haddad; Crippa, José Alexandre de Souza
Source: Frontiers in Pharmacology. Unidade: FMRP
Subjects: ANSIEDADE, DEPRESSÃO, CANABINOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, José Diogo dos Santos et al. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. Frontiers in Pharmacology, v. 13, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.3389/fphar.2022.856846. Acesso em: 09 jun. 2024.
APA
Souza, J. D. dos S., Zuardi, A. W., Guimarães, F. S., Osório, F. de L., Loureiro, S. R., Campos, A. C. de, et al. (2022). Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic. Frontiers in Pharmacology, 13, 1-9. doi:10.3389/fphar.2022.856846
NLM
Souza JD dos S, Zuardi AW, Guimarães FS, Osório F de L, Loureiro SR, Campos AC de, Hallak JEC, Santos RG dos, Silveira ILM, Lima KP, Pacheco JC, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Andraus MH, Crippa JA de S. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-9.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3389/fphar.2022.856846
Vancouver
Souza JD dos S, Zuardi AW, Guimarães FS, Osório F de L, Loureiro SR, Campos AC de, Hallak JEC, Santos RG dos, Silveira ILM, Lima KP, Pacheco JC, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Andraus MH, Crippa JA de S. Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic [Internet]. Frontiers in Pharmacology. 2022 ; 13 1-9.[citado 2024 jun. 09 ] Available from: https://doi.org/10.3389/fphar.2022.856846
Artigo de periodico
Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction (2022)
Franzen, Jaqueline M.; Vanz, Felipe; Werle, Isabel; Guimarães, Francisco Silveira ; Bertoglio, Leandro J.
Source: European Neuropsychopharmacology. Unidades: FMRP, ICB
Subjects: CANABINOIDES, MEMÓRIA, SAÚDE MENTAL, ANSIEDADE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRANZEN, Jaqueline M. et al. Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction. European Neuropsychopharmacology, v. 64, p. 7-18, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.euroneuro.2022.08.002. Acesso em: 09 jun. 2024.
APA
Franzen, J. M., Vanz, F., Werle, I., Guimarães, F. S., & Bertoglio, L. J. (2022). Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction. European Neuropsychopharmacology, 64, 7-18. doi:10.1016/j.euroneuro.2022.08.002
NLM
Franzen JM, Vanz F, Werle I, Guimarães FS, Bertoglio LJ. Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction [Internet]. European Neuropsychopharmacology. 2022 ; 64 7-18.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.euroneuro.2022.08.002
Vancouver
Franzen JM, Vanz F, Werle I, Guimarães FS, Bertoglio LJ. Cannabidiol impairs fear memory reconsolidation in female rats through dorsal hippocampus CB1 but not CB2 receptor interaction [Internet]. European Neuropsychopharmacology. 2022 ; 64 7-18.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.euroneuro.2022.08.002
Artigo de periodico
The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors (2022)
Silva, Nicole Rodrigues; Gomes, Francisco Isaac Fernandes; Lopes, Alexandre Hashimoto Pereira; Cortez, Isadora Lopes; Santos, Jéssica Cristina dos; Silva, Conceição Elidianne Aníbal; Mechoulam, Raphael; Gomes, Felipe Villela ; Cunha, Thiago Mattar; Guimarães, Francisco Silveira
Source: Neurotherapeutics. Unidade: FMRP
Subjects: ANTINEOPLÁSICOS, CANABINOIDES, GÂNGLIOS ESPINHAIS, QUIMIOTERÁPICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Nicole Rodrigues et al. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors. Neurotherapeutics, v. 19, n. 1, p. 434-449, 2022Tradução . . Disponível em: https://doi.org/10.1007/s13311-021-01164-w. Acesso em: 09 jun. 2024.
APA
Silva, N. R., Gomes, F. I. F., Lopes, A. H. P., Cortez, I. L., Santos, J. C. dos, Silva, C. E. A., et al. (2022). The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors. Neurotherapeutics, 19( 1), 434-449. doi:10.1007/s13311-021-01164-w
NLM
Silva NR, Gomes FIF, Lopes AHP, Cortez IL, Santos JC dos, Silva CEA, Mechoulam R, Gomes FV, Cunha TM, Guimarães FS. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors [Internet]. Neurotherapeutics. 2022 ; 19( 1): 434-449.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1007/s13311-021-01164-w
Vancouver
Silva NR, Gomes FIF, Lopes AHP, Cortez IL, Santos JC dos, Silva CEA, Mechoulam R, Gomes FV, Cunha TM, Guimarães FS. The Cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPARγ receptors [Internet]. Neurotherapeutics. 2022 ; 19( 1): 434-449.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1007/s13311-021-01164-w
Artigo de periodico
Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments (2022)
Bayer, Hugo; Stern, Cristina A. J.; Troyner, Fernanda; Gazarini, Lucas; Guimarães, Francisco Silveira ; Bertoglio, Leandro J.
Source: Neuropharmacology. Unidade: FMRP
Subjects: COMPORTAMENTO, CANABINOIDES, TRANSTORNOS DA MEMÓRIA, FARMACOTERAPIA, PLASTICIDADE NEURONAL, CÓRTEX PRÉ-FRONTAL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BAYER, Hugo et al. Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments. Neuropharmacology, v. 205, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2021.108913. Acesso em: 09 jun. 2024.
APA
Bayer, H., Stern, C. A. J., Troyner, F., Gazarini, L., Guimarães, F. S., & Bertoglio, L. J. (2022). Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments. Neuropharmacology, 205, 1-11. doi:10.1016/j.neuropharm.2021.108913
NLM
Bayer H, Stern CAJ, Troyner F, Gazarini L, Guimarães FS, Bertoglio LJ. Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments [Internet]. Neuropharmacology. 2022 ; 205 1-11.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108913
Vancouver
Bayer H, Stern CAJ, Troyner F, Gazarini L, Guimarães FS, Bertoglio LJ. Medial prefrontal cortex mechanisms of cannabidiol-induced aversive memory reconsolidation impairments [Internet]. Neuropharmacology. 2022 ; 205 1-11.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108913
Artigo de periodico
Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial (2022)
Crippa, José Alexandre de Souza ; Pacheco, Júlia Cozar; Zuardi, Antônio Waldo ; Guimarães, Francisco Silveira ; Campos, Alline Cristina de ; Osório, Flávia de Lima ; Loureiro, Sonia Regina ; Santos, Rafael Guimarães dos ; souza, José Diogo dos Santos; Ushirohira, Juliana Mayumi; Ferreira, Rafael Rinaldi; Costa, Karla Cristinne Mancini ; Scomparin, Davi Silveira; Scarante, Franciele Franco ; Santos, Isabela Pires dos; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antonio Lopes da ; Esposito, Danillo Lucas Alves ; Passos, Afonso Dinis Costa ; Dal-Fabbro, Amaury Lelis ; Bellissimo-Rodrigues, Fernando ; Arruda, Eurico ; Scarpelini, Sandro ; Andraus, Maristela Haddad; Nather Junior, Júlio Cesar; Wada, Danilo Tadao; Santos, Marcel Koenigkam ; Santos, Antonio Carlos dos ; Busatto Filho, Geraldo ; Hallak, Jaime Eduardo Cecilio
Source: Cannabis And Cannabinoid Research. Unidades: FMRP, FM
Subjects: COVID-19, CANABINOIDES, ENSAIO CLÍNICO, DOENÇAS INFECCIOSAS, MEDICINA INTERNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CRIPPA, José Alexandre de Souza et al. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, v. 7, n. 5, p. 658-669, 2022Tradução . . Disponível em: https://doi.org/10.1089/can.2021.0093. Acesso em: 09 jun. 2024.
APA
Crippa, J. A. de S., Pacheco, J. C., Zuardi, A. W., Guimarães, F. S., Campos, A. C. de, Osório, F. de L., et al. (2022). Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial. Cannabis And Cannabinoid Research, 7( 5), 658-669. doi:10.1089/can.2021.0093
NLM
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1089/can.2021.0093
Vancouver
Crippa JA de S, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC de, Osório F de L, Loureiro SR, Santos RG dos, souza JD dos S, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Santos IP dos, Mechoulam R, Kapczinski F, Fonseca BAL da, Esposito DLA, Passos ADC, Dal-Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Santos MK, Santos AC dos, Busatto Filho G, Hallak JEC. Cannabidiol for COVID-19 patients with mild to moderate symptoms (CANDIDATE study): a randomized, double-blind, placebo-controlled clinical trial [Internet]. Cannabis And Cannabinoid Research. 2022 ; 7( 5): 658-669.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1089/can.2021.0093
Artigo de periodico
Cannabidiol for the treatment of autism spectrum disorder: hope or hype? (2022)
Pedrazzi, João Francisco Cordeiro; Ferreira, Frederico Rogério; Amaral, Danyelle Silva; Lima, Daniel Antunes; Hallak, Jaime Eduardo Cecilio ; Zuardi, Antonio Waldo; Del Bel, Elaine Aparecida ; Guimarães, Francisco Silveira ; Costa, Karla Cristinne Mancini ; Campos, Alline Cristina de; Crippa, Ana C. S.; Crippa, José Alexandre de Souza
Source: Psychopharmacology. Unidades: FMRP, FORP
Subjects: ANTIPSICÓTICOS, FARMACOTERAPIA, CANABINOIDES, CRIANÇAS EM IDADE PRÉ-ESCOLAR, TRANSTORNO DO DEFICIT DE ATENÇÃO COM HIPERATIVIDADE, TRANSTORNO DO ESPECTRO AUTISTA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEDRAZZI, João Francisco Cordeiro et al. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?. Psychopharmacology, v. 239, n. 9, p. 2713-2734, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00213-022-06196-4. Acesso em: 09 jun. 2024.
APA
Pedrazzi, J. F. C., Ferreira, F. R., Amaral, D. S., Lima, D. A., Hallak, J. E. C., Zuardi, A. W., et al. (2022). Cannabidiol for the treatment of autism spectrum disorder: hope or hype? Psychopharmacology, 239( 9), 2713-2734. doi:10.1007/s00213-022-06196-4
NLM
Pedrazzi JFC, Ferreira FR, Amaral DS, Lima DA, Hallak JEC, Zuardi AW, Del Bel EA, Guimarães FS, Costa KCM, Campos AC de, Crippa ACS, Crippa JA de S. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? [Internet]. Psychopharmacology. 2022 ; 239( 9): 2713-2734.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1007/s00213-022-06196-4
Vancouver
Pedrazzi JFC, Ferreira FR, Amaral DS, Lima DA, Hallak JEC, Zuardi AW, Del Bel EA, Guimarães FS, Costa KCM, Campos AC de, Crippa ACS, Crippa JA de S. Cannabidiol for the treatment of autism spectrum disorder: hope or hype? [Internet]. Psychopharmacology. 2022 ; 239( 9): 2713-2734.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1007/s00213-022-06196-4
Artigo de periodico
Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder (2022)
Bolsoni, Lívia Maria; Crippa, José Alexandre de Souza ; Hallak, Jaime Eduardo Cecilio ; Guimarães, Francisco Silveira ; Zuardi, Antonio Waldo
Source: Psychopharmacology. Unidade: FMRP
Subjects: ANSIEDADE, FARMACOTERAPIA, CANABINOIDES, TRANSTORNOS DA ANSIEDADE, TRANSTORNO DO STRESS PÓS-TRAUMÁTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOLSONI, Lívia Maria et al. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology, v. 239, n. 5, p. 1499-1507, 2022Tradução . . Disponível em: https://doi.org/10.1007/s00213-021-06043-y. Acesso em: 09 jun. 2024.
APA
Bolsoni, L. M., Crippa, J. A. de S., Hallak, J. E. C., Guimarães, F. S., & Zuardi, A. W. (2022). Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. Psychopharmacology, 239( 5), 1499-1507. doi:10.1007/s00213-021-06043-y
NLM
Bolsoni LM, Crippa JA de S, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder [Internet]. Psychopharmacology. 2022 ; 239( 5): 1499-1507.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1007/s00213-021-06043-y
Vancouver
Bolsoni LM, Crippa JA de S, Hallak JEC, Guimarães FS, Zuardi AW. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder [Internet]. Psychopharmacology. 2022 ; 239( 5): 1499-1507.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1007/s00213-021-06043-y
Artigo de periodico
HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia (2022)
Cortez, Isadora Lopes; Silva, Nicole R.; Rodrigues, Naielly S.; Pedrazzi, João Francisco Cordeiro; Del Bel, Elaine Aparecida ; Mechoulam, Raphael; Gomes, Felipe Villela ; Guimarães, Francisco Silveira
Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry. Unidades: FORP, FMRP
Subjects: CANABINOIDES, ESQUIZOFRENIA, FARMACOTERAPIA, COMPORTAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORTEZ, Isadora Lopes et al. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, v. 117, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.pnpbp.2022.110553. Acesso em: 09 jun. 2024.
APA
Cortez, I. L., Silva, N. R., Rodrigues, N. S., Pedrazzi, J. F. C., Del Bel, E. A., Mechoulam, R., et al. (2022). HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 117, 1-9. doi:10.1016/j.pnpbp.2022.110553
NLM
Cortez IL, Silva NR, Rodrigues NS, Pedrazzi JFC, Del Bel EA, Mechoulam R, Gomes FV, Guimarães FS. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022 ; 117 1-9.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.pnpbp.2022.110553
Vancouver
Cortez IL, Silva NR, Rodrigues NS, Pedrazzi JFC, Del Bel EA, Mechoulam R, Gomes FV, Guimarães FS. HU-910, a CB2 receptor agonist, reverses behavioral changes in pharmacological rodent models for schizophrenia [Internet]. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2022 ; 117 1-9.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.pnpbp.2022.110553
Parte de monografia/livro
Medicamentos utilizados no tratamento dos transtornos afetivos (2021)
Joca, Sâmia Regiane Lourenço (colab) ; Guimarães, Francisco Silveira (Editor)
Source: Fundamentos da Psicofarmacologia. Unidades: FMRP, FCFRP
Assunto: PSICOFARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
Medicamentos utilizados no tratamento dos transtornos afetivos. Fundamentos da Psicofarmacologia. Tradução . São Paulo: Atheneu, 2021. . . Acesso em: 09 jun. 2024.
APA
Medicamentos utilizados no tratamento dos transtornos afetivos. (2021). Medicamentos utilizados no tratamento dos transtornos afetivos. In Fundamentos da Psicofarmacologia. São Paulo: Atheneu.
NLM
Medicamentos utilizados no tratamento dos transtornos afetivos. In: Fundamentos da Psicofarmacologia. São Paulo: Atheneu; 2021. [citado 2024 jun. 09 ]
Vancouver
Medicamentos utilizados no tratamento dos transtornos afetivos. In: Fundamentos da Psicofarmacologia. São Paulo: Atheneu; 2021. [citado 2024 jun. 09 ]
Parte de monografia/livro
Bases neurais (2021)
Campos, Alline Cristina de (colab); Guimarães, Francisco Silveira (Editor)
Source: Fundamentos da Psicofarmacologia. Unidade: FMRP
Assunto: PSICOFARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
Bases neurais. Fundamentos da Psicofarmacologia. Tradução . São Paulo: Atheneu, 2021. . . Acesso em: 09 jun. 2024.
APA
Bases neurais. (2021). Bases neurais. In Fundamentos da Psicofarmacologia. São Paulo: Atheneu.
NLM
Bases neurais. In: Fundamentos da Psicofarmacologia. São Paulo: Atheneu; 2021. [citado 2024 jun. 09 ]
Vancouver
Bases neurais. In: Fundamentos da Psicofarmacologia. São Paulo: Atheneu; 2021. [citado 2024 jun. 09 ]
Artigo de periodico
DNA methylation in stress and depression:: from biomarker to therapeutics (2021)
Sales, Amanda Juliana; Guimarães, Francisco Silveira ; Wegener, Sâmia Regiane Lourenço Joca
Source: Acta Neuropsychiatrica. Unidades: FMRP, FCFRP
Subjects: ANTIDEPRESSIVOS, BIOMARCADORES, CÉREBRO, METILAÇÃO DE DNA, DEPRESSÃO, REGULAÇÃO GÊNICA, ESTRESSE PSICOLÓGICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SALES, Amanda Juliana e GUIMARÃES, Francisco Silveira e WEGENER, Sâmia Regiane Lourenço Joca. DNA methylation in stress and depression:: from biomarker to therapeutics. Acta Neuropsychiatrica, v. 33, n. 5, p. 217-241, 2021Tradução . . Disponível em: https://doi.org/10.1017/neu.2021.18. Acesso em: 09 jun. 2024.
APA
Sales, A. J., Guimarães, F. S., & Wegener, S. R. L. J. (2021). DNA methylation in stress and depression:: from biomarker to therapeutics. Acta Neuropsychiatrica, 33( 5), 217-241. doi:10.1017/neu.2021.18
NLM
Sales AJ, Guimarães FS, Wegener SRLJ. DNA methylation in stress and depression:: from biomarker to therapeutics [Internet]. Acta Neuropsychiatrica. 2021 ; 33( 5): 217-241.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1017/neu.2021.18
Vancouver
Sales AJ, Guimarães FS, Wegener SRLJ. DNA methylation in stress and depression:: from biomarker to therapeutics [Internet]. Acta Neuropsychiatrica. 2021 ; 33( 5): 217-241.[citado 2024 jun. 09 ] Available from: https://doi.org/10.1017/neu.2021.18
Artigo de periodico
Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects (2021)
Sartim, Ariandra Guerini; Marques, J.; Silveira, Kennia Moura; Nunes, Pedro Henrique Gobira; Guimarães, Francisco Silveira ; Wegener, G.; Wegener, Sâmia Regiane Lourenço Joca
Source: Neuropharmacology. Unidades: FMRP, FCFRP
Subjects: ANTIDEPRESSIVOS, COMPORTAMENTO ANIMAL, CANABINOIDES, DEPRESSÃO, HIPOCAMPO, ATIVIDADE MOTORA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SARTIM, Ariandra Guerini et al. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. Neuropharmacology, v. 195, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.neuropharm.2021.108679. Acesso em: 09 jun. 2024.
APA
Sartim, A. G., Marques, J., Silveira, K. M., Nunes, P. H. G., Guimarães, F. S., Wegener, G., & Wegener, S. R. L. J. (2021). Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. Neuropharmacology, 195. doi:10.1016/j.neuropharm.2021.108679
NLM
Sartim AG, Marques J, Silveira KM, Nunes PHG, Guimarães FS, Wegener G, Wegener SRLJ. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects [Internet]. Neuropharmacology. 2021 ; 195[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108679
Vancouver
Sartim AG, Marques J, Silveira KM, Nunes PHG, Guimarães FS, Wegener G, Wegener SRLJ. Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects [Internet]. Neuropharmacology. 2021 ; 195[citado 2024 jun. 09 ] Available from: https://doi.org/10.1016/j.neuropharm.2021.108679

USP Schools

ReP

Filtros

Document Types

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Publisher

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Normalized affiliation

Non normalized affiliation

Countries of institutions of collaboration